Primary ciliary dyskinesia (PCD) is a genetic disease characterised by defective motility of cilia resulting in impaired mucociliary clearance and infertility in most cases.1 2

Decreased ciliary motility with secondary microbial colonisation in the airways leads to chronic airway inflammation and bronchiectasis. Oxidants and inflammatory mediators released from activated inflammatory cells in airways may lead to the induction of inducible nitric oxide synthase (iNOS) producing nitric oxide (NO) and inductible heme oxygenase (HO-1) releasing carbon monoxide (CO). In pulmonary diseases associated with chronic airway inflammation, such as asthma, expression of iNOS and HO-1 is increased in the airways and levels of NO and CO are raised in exhaled breath.3 4 Increased levels of exhaled NO (eNO) and CO (eCO) correlate with other markers of airway inflammation in asthma.5 6 Concentrations of eNO and eCO are also increased in patients with bronchiectasis, which may reflect iNOS and HO-1 expression in macrophages and neutrophils in the airways of these patients.7 8

Patients with PCD may represent a unique group of subjects, however, as eNO and nasal NO (nNO) levels are abnormally low in patients with PCD and documented bronchiectasis.9 10 Nasal NO is also lower in children with Kartagener’s syndrome (a condition in which PCD is associated with situs inversus) compared with healthy control children,11 suggesting a defect in the function and/or expression of NO synthases. The level of eNO and nNO in patients with PCD may not reflect the chronic inflammatory process in the airways and might not be used as a non-invasive inflammatory marker, but it may be useful in diagnosing PCD as a cause of bronchiectasis in these patients. Expression and/or function of HO-1, however, may not be defective in patients with PCD and the level of eCO may reflect the chronic inflammatory process in these subjects.

We have therefore measured eNO, eCO, and nNO levels simultaneously in bronchiectatic patients with PCD and compared these values with those obtained from age matched healthy subjects, and patients with non-PCD bronchiectasis, with and without cystic fibrosis (CF). We included bronchiectatic patients with CF because CF may present with symptoms of chronic inflammation of the upper and/or lower airways, similar to PCD. Furthermore, eNO and nNO levels are lower than normal not only in PCD, but also in CF.12

METHODS

Subject characteristics

Four groups of subjects participated in the study (tables 1 and 2). Patients with bronchiectasis (PCD and non-PCD without CF) were recruited from the Host Defence Unit at the Royal Brompton Hospital and control subjects were recruited from staff members and examined at the Asthma Laboratory at the Royal Brompton Hospital, London. Bronchiectatic patients with CF were recruited from those attending an outpatient clinic for a scheduled visit at the National Koranyi Institute for Pulmonology, Budapest and examined at the Department of Pathophysiology at the same institute. Patients had no evidence of exacerbations for at least 4 weeks before the study. PCD was proved clinically and confirmed functionally (saccharin test >60 min and abnormal ciliary beat frequency/dyskinetic beat pattern) and morphologically at the PCD clinic of the Royal Brompton Hospital. Patients with PCD had ciliary defects (dynein arm abnormalities, n=6; microtubular transposition, n=1, documented by electron microscopy of ciliary nasal epithelium obtained either by nasal brushing or biopsy).
or primary ciliary disorientation (n=7, verified using a computerised improvision image analysis system). Bronchiectasis was diagnosed clinically and confirmed by high resolution computed tomographic (CT) scanning of the thorax in all patients. CF was confirmed by genetic analysis and a positive sweat test (chloride values >60 mM). Patients with atopy, asthma, or reversible (>12%) airway obstruction were excluded from the study. Normal control subjects had no history of chronic disease, were not receiving any regular medication, and had been free of respiratory infections for at least 6 weeks before the study. None of the subjects reported being current cigarette smokers or being exposed to smoke for more than 0.5 hours/day; this was confirmed by testing their urinary cotinine level with NicCheck I (DynaGen Inc, Cambridge, MA, USA).

The study protocol was approved by the research ethics committees of both institutions and informed consent was obtained from all subjects.

### Study design

Exhaled NO, eCO, and nNO were measured and spirometric tests were then performed. Forced expiratory volume in 1 second (FEV₁) and forced vital capacity (FVC) were measured. Forced expiratory volume in 1 second (FEV₁) and forced vital capacity (FVC) were measured using a dry spirometer (Vitalograph, Buckingham, UK) and the best of three manoeuvres was expressed as a percentage of the predicted normal value.

### Table 1  Mean (SD) subject characteristics

<table>
<thead>
<tr>
<th></th>
<th>Bronchiectasis (n=37)</th>
<th>Bronchiectasis (n=14)</th>
<th>Bronchiectasis (n=31)</th>
<th>Bronchiectasis (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>33 (2.8)</td>
<td>35 (6.4)*</td>
<td>45 (5.1)*</td>
<td>25.7 (2.4)</td>
</tr>
<tr>
<td><strong>Sex (M/F)</strong></td>
<td>20/17</td>
<td>8/6</td>
<td>16/15</td>
<td>12/8</td>
</tr>
<tr>
<td><strong>FEV₁ (% predicted)</strong></td>
<td>94 (0.8)</td>
<td>51 (5.1)†</td>
<td>58 (6.1)†</td>
<td>53 (5.9)†</td>
</tr>
<tr>
<td><strong>FVC (% predicted)</strong></td>
<td>99 (0.4)</td>
<td>72 (4.2)†</td>
<td>77 (3.1)†</td>
<td>74 (3.3)†</td>
</tr>
<tr>
<td><strong>FEV₁/FVC</strong></td>
<td>0.81 (0.001)</td>
<td>0.62 (0.04)†</td>
<td>0.65 (0.02)†</td>
<td>0.62 (0.04)†</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>None</td>
<td>7 IS</td>
<td>19 IS; 2 OS</td>
<td>8 IS</td>
</tr>
</tbody>
</table>

**PCD= primary ciliary dyskinesia; CF= cystic fibrosis; FEV₁=forced expiratory volume in 1 second; FVC=forced vital capacity; IS=inhaled steroids; OS=oral steroids.**

### Table 2  Clinical characteristics of patients with bronchiectasis

<table>
<thead>
<tr>
<th></th>
<th>Without CF</th>
<th>With CF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neonatal respiratory symptoms</strong></td>
<td>6 (43)</td>
<td>2 (6)</td>
</tr>
<tr>
<td><strong>Chronic sputum production</strong></td>
<td>12 (86)</td>
<td>23 (74)</td>
</tr>
<tr>
<td><strong>Rhinosinusitis</strong></td>
<td>13 (93)</td>
<td>3 (10)</td>
</tr>
<tr>
<td><strong>Otitis media</strong></td>
<td>11 (79)</td>
<td>2 (6)</td>
</tr>
<tr>
<td><strong>Situs inversus</strong></td>
<td>6 (43)</td>
<td>0 (0)</td>
</tr>
<tr>
<td><strong>Infertility/subfertility</strong></td>
<td>11 (79)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Data are given as number (%) of patients.

<table>
<thead>
<tr>
<th></th>
<th>Non-PCD</th>
<th>PCD Without CF</th>
<th>PCD With CF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>33 (2.8)</td>
<td>35 (6.4)*</td>
<td>45 (5.1)*</td>
</tr>
<tr>
<td><strong>Sex (M/F)</strong></td>
<td>20/17</td>
<td>8/6</td>
<td>16/15</td>
</tr>
<tr>
<td><strong>FEV₁ (% predicted)</strong></td>
<td>94 (0.8)</td>
<td>51 (5.1)†</td>
<td>58 (6.1)†</td>
</tr>
<tr>
<td><strong>FVC (% predicted)</strong></td>
<td>99 (0.4)</td>
<td>72 (4.2)†</td>
<td>77 (3.1)†</td>
</tr>
<tr>
<td><strong>FEV₁/FVC</strong></td>
<td>0.81 (0.001)</td>
<td>0.62 (0.04)†</td>
<td>0.65 (0.02)†</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>None</td>
<td>7 IS</td>
<td>19 IS; 2 OS</td>
</tr>
</tbody>
</table>

### Statistical analysis

Age, FEV₁, and FVC values are given as mean (SE). Mediator values are expressed as median (range). Differences between groups were analysed non-parametrically using the Kruskal-Wallis test (p values of <0.0001 were considered significant). Pairwise comparisons using the Dunn’s multiple comparison test were then carried out.

Spearman’s rank correlation was used to determine the relationship between variables. Mean – 2SD values were calculated for nNO to obtain a cut off value for determining the specificity and sensitivity of the measurements. A p value of <0.05 was considered significant.

### RESULTS

#### Exhaled NO

The concentration of eNO in patients with PCD and CF was significantly lower than that in healthy subjects (median (range) 2.1 (1.3–3.5) ppb; p<0.001 and 3.0 (1.5–7.5) ppb;
significantly different from those in normal subjects. Patients with
non-CF bronchiectasis (680 (310–1000) ppb) were not signifi-
cantly different from patients (p<0.01). Nasal NO values of patients with non-PCD,
but their nNO level was significantly higher than that of PCD
patients: 5 (2–11) ppm; the values in both groups were
significantly higher than those of the normal control group
(p<0.01 and p<0.001, respectively). No significant difference
was detected between patients with and without steroid
treatment.

Sensitivity and specificity of the measurement of eNO
and nNO
The sensitivity of eNO measurement in selecting PCD patients
(number of PCD patients with low eNO reading/number of all
patients with PCD in the population) was 79% when a cut off
value of 2.4 ppb was chosen. The specificity of eNO measure-
ment (number of non-PCD bronchiectatic patients with nega-
tive test/number of all non-PCD bronchiectatic patients) at
this cut off value was 85%. The predictive value of a positive
test (PPV; percentage of PCD patients with a positive result)
was 69% and the predictive value of a negative test (NPV; per-
centage of patients with a negative test result from those
patients who did not have PCD) was 94%.

The sensitivity of nNO measurement was 93% and the spe-
cificity was 95% when the mean – 2SD of the nNO level in
healthy subjects (187 ppb) was used as a cut off value (only
two patients with CF had a value below the cut off level). The
PPV of nNO measurement was 87% and its NPV was 97% in
discriminating between PCD and non-PCD bronchiectatic
patients.

If a positive result was described as low values in both eNO
and nNO readings together in the same patient (eNO
<2.4 ppb + nNO <187 ppb), this identified PCD patients with
a specificity of 98%, PPV of 92%, and NPV of 93%.

Correlations between variables
There was no correlation between lung function and eNO,
nNO, or eCO values either when data were pooled or when
data from steroid treated and non-treated subgroups were
analysed separately or different subject groups were analysed
separately (data not shown). Similarly, no relation was found
between eNO and nNO readings or between eNO, nNO, eCO
values and the age of subjects.

DISCUSSION
We have assessed the clinical usefulness of the simultaneous
measurement of eNO and nNO in discriminating between
PCD and other types of bronchiectasis. The reported specificity
and sensitivity of the simultaneous measurements suggest
that their combined use can be a valuable non-invasive
screening tool for PCD. The measurement of nNO by itself has
good diagnostic value. However, if a low nNO value is
observed, determination of eNO and the combined evaluation
of the two test results improves the diagnostic value by
increasing its specificity and PPV. The measurement of eNO,
however, cannot be used by itself for this purpose because of
its low sensitivity and PPV. This study shows for the first time

Figure 1  Exhaled nitric oxide, nasal nitric oxide, and exhaled
carbon monoxide concentrations in normal subjects, patients with
primary ciliary dyskinesia (PCD) with documented bronchiectasis,
and patients with non-PCD bronchiectasis with and without cystic
fibrosis (CF). The Kruskal-Wallis test showed significant differences
between mediator levels (p<0.0001).

Nasal NO
Nasal NO measurements were obtained in all patients with
PCD and CF, in 20 non-PCD, non-CF bronchiectatic patients,
and in 17 healthy subjects. The nNO level was markedly
reduced in bronchiectatic patients with PCD (median (range)
54.5 (5–269) ppb) compared with normal controls (663 (322–
1343) ppb; p<0.001). Bronchiectatic patients with CF also had
lower than normal levels of nNO (343 (30–997) ppb; p<0.05),
but their nNO level was significantly higher than that of PCD
patients (p<0.01). Nasal NO values of patients with non-PCD,
non-CF bronchiectasis (680 (310–1000) ppb) were not signifi-
cantly different from those in normal subjects. Patients with
PCD had significantly lower nNO levels than non-PCD,
non-CF bronchiectatic patients (p<0.001, fig 1). None of the
patients was using nasal steroids and, when data were
analysed without nNO values from patients on treatment with
oral steroids (n=2), similar differences were found between
the groups.

Exhaled CO
Levels of eCO were significantly higher than normal in all
patient groups (bronchiectasis with PCD: 4.5 (3–24) ppm,
p<0.001; non-PCD, non-CF bronchiectasis: 5 (3–15) ppm,
p<0.001; CF: 5.3 (2–23) ppm, p<0.001; controls: 3 (0.5–
5) ppm). No differences in eCO values were seen between the
different groups of patients (fig 1). There were a few outliers in
eCO data (24 ppm in the PCD group, 19 and 23 ppm in the CF
group) so the results were also analysed without these values,
giving the following results: PCD patients: 4 (3–8) ppm, CF
patients: 5 (2–11) ppm; the values in both groups were
significantly higher than those of the normal control group
(p<0.01 and p<0.001, respectively). No significant difference
was detected between patients with and without steroid
treatment.

Correlations between variables
There was no correlation between lung function and eNO,
nNO, or eCO values either when data were pooled or when
data from steroid treated and non-treated subgroups were
analysed separately or different subject groups were analysed
separately (data not shown). Similarly, no relation was found
between eNO and nNO readings or between eNO, nNO, eCO
values and the age of subjects.
that patients with PCD have lower nNO values than those with any other types of bronchiectasis. It also shows that eNO values are lower in patients with PCD than in those with non-PCD non-CF bronchiectasis, although there is no difference in eNO values between patients with PCD and CF bronchiectasis. In addition, we have shown that the eCO concentration is increased in patients with PCD to a similar extent to that in other types of bronchiectasis.

There was a significant difference in the mean age of the patients with CF and the other groups. This difference, however, probably did not influence our results because eNO and eCO values have been found not to be age related in adults.17 19 Furthermore, there was no evidence of any relation between age and nNO values.

A modest increase in eNO levels in non-PCD, non-CF bronchiectatic patients compared with healthy subjects, with some overlap between the two groups. This increase was smaller than we had observed in patients with atopic asthma.18 This fits well with the notion that production of NO is linked to eosinophilic inflammation and that eNO levels are not as high in patients with airway inflammation dominated by neutrophils as in those with allergic asthma.

Some of our patients were treated with inhaled and/or oral steroids, but we could not detect any difference in eNO and eCO levels between patients with or without this treatment. Corticosteroids have been shown to reduce eNO levels profoundly in asthmatic patients20 and to decrease nNO levels in patients with allergic rhinitis.21 However, in patients with chronic supplicative upper and/or lower airway inflammation the results are somewhat contradictory. No difference was found in the eNO level between steroid treated and non-treated patients with CF,22 while in patients with bronchiectasis one study showed a difference in the eNO level but another did not.23 Differences between the results of these studies can be explained by differences in the techniques used for eNO measurement and by the fact that all of these studies (including the present one) were cross sectional. Prospective follow up studies are required to investigate the possible influence of steroid treatment on eNO values in bronchiectatic patients.

Because nasal symptoms (nasal polyps, sinusitis, persistent serous otitis media) are the main presenting features of PCD, it is important to consider the diagnosis of PCD in these cases. Could the measurement of nNO and eNO help to exclude PCD as an underlying cause of chronic upper airway symptoms? Nasal NO levels are extremely low in PCD. However, low eNO levels are also found in patients with chronic rhinosinusitis24 25 which may therefore influence the diagnostic value of nNO measurement in discriminating between patients with PCD and those with rhinosinusitis from other causes. Although not specifically investigated in the present study, subjects with non-PCD, non-CF upper airway and sinus diseases had normal NO levels in the lower airways.26 The use of the combination of eNO and nNO measurements would therefore still have good specificity in identifying PCD.

In contrast to the results on NO levels, we found that eCO levels were raised in all patient groups studied compared with controls, with no difference between different conditions. In chronic airway infections increased HO-1 protein expression may result from the induction of the enzyme by inflammatory mediators such as interleukin-1β, tumour necrosis factor-α, interferon-γ and hydrogen peroxide (H₂O₂) present in the inflamed airways.27–29 HO-1 may be induced in various cells in the respiratory tract, including airway macrophages, epithelial cells,30 and infiltrating inflammatory cells such as neutrophils. In the present study there was no correlation between eCO levels and FEV₁. This is not surprising as the decrease in FEV₁ may be the result of structural changes due to repeated inflammation while increased eCO levels are more closely linked with the ongoing inflammatory process. Increased CO production may have multiple functions in the airways including antioxidant, pro-inflammatory, and anti-inflammatory effects.31 The finding that eCO is increased equally in different inflammatory airway diseases including asthma,32 bronchiectasis,33 and CF34 suggests that CO production has a profound link with inflammatory processes regardless of their atopic or non-atopic nature.

In conclusion, this study has shown that combined measurement of eNO and nNO levels discriminates between bronchiectatic patients with PCD and those with bronchiectasis from other causes, which suggests that this measurement can be used as a non-invasive screening tool for PCD. On the other hand, increased levels of eCO found in all patient groups indicate that the activation of CO production is generally involved in these airway conditions.

Authors’ affiliations
S Loukides, T Wadehouse, P J Cole, S A Kharitonov, P J Barnes, Department of Thoracic Medicine, National Heart and Lung Institute at Imperial College, London, UK
I Horváth, É Csiszér, Department of Pathophysiology, National Koranyi Institute for Pulmonology, Budapest, Hungary

This study was supported by the Hungarian National Scientific Research Foundation (OTKA T030340) and by a joint grant of the British Council and the Hungarian OMFB (grant number: GB-31/98).

REFERENCES

www.thoraxjnl.com
LUNG ALERT

Thrombolysis for submassive pulmonary embolism

This was a randomised placebo controlled trial of alteplase (100 mg over 2 hours) with heparin v. placebo with heparin in 256 patients with submassive pulmonary embolism (PE) defined as echocardiographically detected PE; pulmonary artery hypertension with confirmation of PE by spiral computed tomography (CT); precapillary pulmonary hypertension with confirmation by CT; or new electrocardiographic signs of right ventricular strain followed by CT. Exclusion criteria included age >80 years, haemodynamic instability, and presentation more than 96 hours after onset of symptoms. In the alteplase group there was less escalation of treatment (p=0.004) and a greater chance of 30 day event free survival (p=0.005). There was no difference in mortality or adverse events between the two groups.

This is the largest trial of thrombolysis in PE ever conducted, and it looks at the controversial group of patients with submassive PE showing significant benefit of alteplase. The absence of haemorrhagic complications was surprising.

T A R Seemungal
TSeemungal@aol.com
Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia

I Horváth, S Loukides, T Wodehouse, E Csiszér, P J Cole, S A Kharitonov and P J Barnes

Thorax 2003 58: 68-72
doi: 10.1136/thorax.58.1.68

Updated information and services can be found at:
http://thorax.bmj.com/content/58/1/68

These include:

**Supplementary Material**
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2004/05/19/58.1.68.DC1

**References**
This article cites 27 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/58/1/68#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Errata**
An erratum has been published regarding this article. Please see next page or:
/content/59/6/543.1.full.pdf

**Topic Collections**
Articles on similar topics can be found in the following collections

- Ear, nose and throat/otolaryngology (218)
- Cystic fibrosis (525)
- Inflammation (1020)
- Screening (epidemiology) (366)
- Screening (public health) (366)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
PostScript

LETTERS TO THE EDITOR

Variations in mortality in acute COPD may reflect nihilism as well as resources

I read with great interest the paper by Roberts et al., and the accompanying editorial by Rudolf. The study highlights important variations in the outcomes of patients with a common chronic disease, and once more illustrates that doctor:patient ratios may be an important contributor to this. It is also likely that some of the observed variation may arise as a result of variations in decision making by individual clinicians.

A recent study carried out in the eight hospitals in the Heart of England Critical Care network interviewed 98 clinicians who made to be involved in decisions for patients with chronic obstructive pulmonary disease (COPD). Each had made a median of 10 end of life decisions for COPD patients in the previous 12 months. There was considerable variability in the decision whether or not to admit identical patients to the critical care unit, with those choosing not to admit patients forming very pessimistic predictions of outcome compared with clinicians who would admit. It seems possible that poor outcomes for patients with COPD may not simply reflect a lack of resources, but also therapeutic nihilism that may have grown up over the years in response to the cognitive dissonance that arose when beds in critical care units could not be found for COPD patients in extremis. It seems likely that reversing variations in outcome will require both changes in resources and changes in clinicians’ expectations. In this respect, the GMC guidance on withholding and withdrawing life prolonging treatments may well be helpful, particularly section 20 which recommends that “where there is a reasonable degree of uncertainty about the appropriateness of providing a particular treatment, treatment which may be of some benefit to the patient should be started until a final decision can be made”. The Heart of England Critical Care network study over one third of clinicians would not admit a 75 year old COPD patient with single organ respiratory failure, yet in a recent study of over 3700 admissions of COPD patients median age 67 years to UK intensive care units, those with single organ respiratory failure had a hospital survival of over 70%.

It is important that chest physicians continue to be strident advocates for COPD (COPD). Care network interviewed 98 clinicians who hospitals in the Heart of England Critical Care units, those with single organ respiratory failure, yet in a recent study of 75 year old COPD patient with single organ respiratory failure, and suggests that respiratory physicians need to be advocates for their patients in this arena.

Attitudes and beliefs in what might be achieved are important but are difficult to measure in clinical practice. They might account for some of the variation in outcome but, if so, the therapeutic nihilism would have to vary systematically between whole hospitals to be a factor in our study. Admission to the ITU depends on more than the individual attitude of the referring doctor. A lack of availability of beds may raise a cause for concern. Perrin’s paper provides hope of a generic match although individual disagreements may still occur. It is, however, not only admission to the ITU that matters, as in many hospitals non-invasive ventilatory support is provided on general wards by respiratory units without input from intensivists.

In the BTS/RCP 2003 national audit of the acute care of COPD patients, 95% of all acute admitting sites have now registered to participate and data collection is nearing completion. Within the clinical data gathering there is a question that attempts to document clinical decision making when a patient eligible for ventilation on blood gas criteria does not receive ventilatory support. In addition, data regarding available resources such as ITU beds, bed occupancy, and numbers of ITU candidates transferred off site will be recorded. We may be in a position to shed further light on the issues of individual versus institutional nihilism or rationing in due course.

C M Roberts, M G Pearson
Chest Clinic, Whips Cross University Hospital,
London E11 1NQ, UK, mike@2doctors.freeserve.co.uk

References


Authors’ reply

We thank Dr Wildman for his letter suggesting a further possible reason for the variation in outcome that we reported for the acute care of COPD patients in different hospital centres. In a further unpublished multiple regression analysis of the RCP/BTS 2001 audit we found that 26% of the variation in the outcome of death at 90 days following admission could be accounted for by factors measured in the study that included patient characteristics such as performance status and resource and organisational issues, as described in our paper. Dr Wildman suggests that individual clinicians might vary in determining admission to the ITU for COPD patients in respiratory failure, and suggests that respiratory physicians need to be advocates for their patients in this arena.

If you have a burning desire to respond to a paper published in Thorax, why not make use of our “rapid response” option? Log on to our website (www.thoraxjnl.com), find the paper that interests you, and send your response via email by clicking on the “letters” option in the box at the top right hand corner. Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read letters” on our homepage.

The editors will decide as before whether to also publish it in a future paper issue.

J M Wildman
Health Services Research Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HY, UK; martin.wildman@lshtm.ac.uk

Do inhaled corticosteroids slow FEV1 decline in COPD after all?

I question the findings of the meta-analysis by Sunderland et al. and the content of the associated editorial by Burge and Lewis. The meta-analysis has drawn from available long term data from randomised controlled studies (RCTs) of inhaled corticosteroids (ICS) in chronic obstructive airways disease (COPD). The whole purpose of meta-analysis is to analyse such data systematically to answer a question. This study seems to use the data selectively to demonstrate an effect. Another recent meta-analysis—in my opinion properly conducted—drew on the same studies and reached the opposite conclusion.

The fact is that four long term, adequately powered RCTs have examined the effect of ICS, and all of these studies failed to detect an effect of ICS on the primary outcome measure of decline in forced expiratory volume in

References

1 second (FEV1). There may be a subset of people in whom the exacerbation rate is reduced, which was a secondary outcome in some of these studies.

In any case, as the authors point out, an annual difference of 7.7–9.9 ml in FEV1 decline compared with placebo is of “debatable clinical importance”. It is hardly something to shout about, as occurred following this publication (probably egged on by the editorial) which was quoted in the GP press as suggesting that current widespread ICS use (albeit “off-label”) was now clinically justified.

Another major problem with this study is that it does not analyse harm. For example, the largest RCT showed a significant reduction in bone mineral density of the lumbar spine and femur in patients receiving inhaled triamcinolone. People with COPD likely to receive ICS are frail and have poor mobility, so this finding raises particular concern as they are more likely to fall and falls could result in fracture. Even if inhaled triamcinolone is not used in the UK, fluticasone is. Fluticasone has been the subject of particular cautionary advice because of its ability to cause systemic effects at high doses. If there is indeed a marginal clinical benefit from using these drugs, I think these people deserve a better assessment of risk and benefit than was presented in this meta-analysis and the accompanying editorial. The editorial claimed that it is no longer ethical to do more long term trials: surely the conclusion is the opposite? We need better data to justify the widespread use of ICS in COPD.

M G Duerden
Department of Medicine, University of Keele, Staffordshire ST5 5BG, UK; martin@theuerdens.co.uk

Ethics of placebo controlled studies of inhaled steroids for COPD

The meta-analysis by Sutherland et al10 of the effect of inhaled corticosteroids on the progression of airflow limitation in patients with chronic obstructive pulmonary disease (COPD) found a small improvement in forced expiratory volume in 1 second (FEV1) of 7.7–9.9 ml/year (95% CI −11.2 to 1.2) which is similar to the results of the meta-analysis performed by Highland et al8 (−5 ml/year (95% CI −11.2 to 1.2)) using a very similar data set. The meta-analyses employed slightly different study selection criteria and analytical techniques, and questioned the clinical significance of such small differences in FEV1. The selected primary studies suffered from potential drop-out bias and significant selection bias. None of the studies were subjected to these meta-analyses excluded patients with a bronchodilator response.7 Studies of asthma and COPD as separate entities are limited because asthma and COPD (observed in cross sections) represent different clinical stages of the same underlying aetiology evolving over time.4 Given all the uncertainties, questions and limitations, Highland et al10 concluded (correctly in my opinion) that “additional studies are needed to evaluate the effects on quality of life, risk for systemic side effects, dose-response relationships in corticosteroid-responsive patients, and the economic effect of inhaled corticosteroids”. On the other hand, in an editorial accompanying the paper by Sutherland et al, Burge and Lewis5 state: “It is no longer ethical to do more long term placebo controlled studies [of inhaled corticosteroids in COPD].” Given the uncertainties, questions and limitations which Burge and Lewis acknowledged, I was puzzled by this statement and would like to ask them why they reached this conclusion.

D L Hahn
Dean Medical Center, East Clinic, 1821 S Stoughton Road, Madison, WI 53716, USA; dlhahn@wisc.edu

References

6 Burge PS, Lewis SA. Inhaled steroids slow the rate of decline of FEV1 in patients with COPD after all? Thorax 2003;58:911–3.

Authors’ reply

To make randomised controlled studies ethical, the investigator must believe that neither no treatment is known to be superior to the other. If the trial is to be placebo controlled, the investigator must believe that no non-allowed treatment is known to be of benefit. Both Drs Duerden and Hahn want more placebo controlled trials of inhaled corticosteroids (ICS) in COPD before they recommend their use. I must point out that ICS were of established benefit in reducing exacerbations of COPD, so any future placebo controlled study would need to be in patients without a history of exacerbations. As exacerbations are associated with disease severity, and as about 80% of patients with an FEV1 <50% predicted have at least one exacerbation over a 3 year period,2 any trial would need to be in those with early disease. The Copenhagen City Lung Study found that inhaled budesonide 800 µg/day had no benefit in a population of smokers with a reduced FEV1/FVC ratio, the majority of whom had an FEV1 above 80% predicted.3 This leaves the group with an FEV1 between 50% and 80% predicted, many of whom have not been identified by their medical practitioners. This was the group included in the EUROSCOP and Lung Health 2 studies, where the results included in the meta-analysis were the most divergent, probably because of the relatively low dose of ICS used in the Lung Health study.1,4 In the symptomatic patient with more severe disease, the combination of a long acting β2 agonist and an ICS has been shown to be superior to either alone and is now the treatment of choice.5,6 This leaves the presymptomatic population in whom a decline in FEV1 is the only practical outcome measure. No randomised study using an intention to treat analysis has shown a reduction in FEV1 decline with ICS treatment in any disease, including ICS in asthma, although several studies have shown an improvement in FEV1 with ICS in COPD.7–10 Our editorial tried to explain why changes in FEV1 decline did not show in patients with COPD. Patients with progressive disease are likely to be given ICS by their clinicians outside any trial, reducing the power of any study.

Any treatment should weigh the potential risks against any benefit. Dr Duerden wants a better analysis of the risks of ICS in patients with COPD, particularly related to bone loss, and points out the reduced bone mineral density in the triamcinolone group in the Lung Health 2 study.11 The reported results are in 359/412 of a convenience sample who had three measurements of bone density. After 3 years the lumbar spine density reduced from 0.988 to 0.985 g/cm2, and the femoral neck from 0.762 to 0.747 g/cm2 in the triamcinolone group. EUROSCOP studied bone density measurements in 194 subjects’ at 1 year and very small changes which were significantly less at the femoral neck and the budesonide group (0.04%/year v 0.36%/year in the placebo group). Randomised controlled studies are probably not the best method for assessing the extent of long term adverse effects, but the evidence from the randomised studies to date shows that the risks are relatively minor compared with the risks of death from the natural progression of the disease. Introducing ICS at an earlier stage may alter the risk/benefit ratios. The adverse effects on the bones are probably best studied in asthmatics of whom many are already taking long term ICS in equivalent doses.

There is a striking difference between the way that cardiac and respiratory physicians greet new treatments whose individual effects are present but relatively minor. There has been a national smoking drive and cardiac deaths attributed to the combination of several treatments with modest individual effects. This has resulted in more smokers living to develop significant COPD. It is likely that improvements in the quality and quantity of life in patients with COPD will come from a combination of treatments, among which ICS have a place.
unanswered questions are—at which stage to start and what dose to use? Randomised trials in these areas are badly needed. They will require large numbers, enthusiasm from respiratory clinicians, and are likely to need public rather than pharmaceutical industry funding.

P S Burge
Birmingham Heartlands Hospital, Birmingham
B9 5SS, UK; sherwood.burge@heartlands.nhm. ac.uk

S Lewis
Division of Respiratory Medicine, City Hospital, Nottingham, UK

References
1 Burge PS, Lewis SA. So inhaled steroids slow the rate of decline of FEV1 in patients with COPD after Lancet 2003;361:589–91.

Delays in diagnosis of OSAHS
We very much enjoyed the first paper in the review series on sleep apnoea and Stradling and Davies’s honest appraisal of the current difficulties in defining disease and the lack of a relationship between symptoms and the results of investigations.1 One of the possible solutions to truly determining the size of the health burden associated with the obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is that much of the burden may occur before the diagnosis is made. Others have shown how spurious hospital resource usage and cardiovascular medication is high in those with undiagnosed obstructive sleep apnoea.2,3 We administered a questionnaire to 166 consecutive patients with diagnosed OSAHS on continuous positive airway pressure treatment and asked them to identify how long they could recall having symptoms at the time of diagnosis. In 155 cases (92.8%) someone had previously complained of the patient’s loud snoring and first mention of this had been made a median of 12 years (range 2–52) before diagnosis of OSAHS. In 84.3% of respondents excessive daytime sleepiness had been present for a median of 8 years (range 0.5–62) and 133 patients (80.1%) reported that their bed partner had witnessed apnoea a median of 8 years (range 1–49) before diagnosis. We also found that, of the 119 (71.7%) who were drivers, 26 (21.8%) had reported at least one or more automobile crashes in the previous 5 years, with seven respondents having had two and one having had four. These results suggest a lack of awareness of sleep related breathing disorders among the general population and probably among health professionals. The delay in diagnosis is likely to have significant effects on morbidity, and in recent preliminary work it has been shown that those with OASHS have structural changes in brain morphology compared with healthy controls.4 In addition to the health and quality of life benefits to the individual to be gained by prompt diagnosis, there are also economic aspects in favour of prompt diagnosis and treatment5 and early benefits in terms of driving performance.6

R Ghiassi, K Murphy, M R Partridge
The Sleep Laboratory, Charing Cross Hospital, London W6 8RF, UK

Correspondence to: Professor M R Partridge, Department of Respiratory Medicine, Imperial College London, Charing Cross Campus, London W6 8RP, UK; m.partridge@imperial.ac.uk

References
1 Stradling JR, Davies RJO. Sleep - 1: Obstructive sleep apnoea/hypopnoea syndrome: definitions, epidemiology and natural history. Thorax 2004;59:73–8

Prophylactic antibiotic treatment of bronchiectasis with azithromycin
Once a treatable cause of bronchiectasis such as hypogammaglobulinaemia has been excluded, management largely involves physiotherapy and treatment of infective exacerbations with appropriate antibiotics.7 In a proportion of patients this is not adequate to prevent frequent infective exacerbations. Prophylactic antibiotic treatment can be used to try to prolong the exacerbation free period. This may be administered orally, via a nebuliser, or using a cyclical regimen of azithromycin. This may be administered orally, via a nebuliser, or using a cyclical regimen of azithromycin. There is compelling evidence that, in patients with bronchiectasis who are receiving ineffective treatment for exacerbations, prophylactic treatment with azithromycin will reduce the frequency of exacerbations. In patients with bronchiectasis who have had a documented infective exacerbation within the last 6 months, prophylactic azithromycin was administered for 6 months. The results showed a reduction in exacerbations in almost all patients, with a significant fall in the number of exacerbations in the last 3 months of the study. The mean (SD) length of time experienced were mild and mainly gastro-intestinal. Five patients were on long term oral corticosteroids with no change in dosage, in two new inhaled corticosteroids were introduced, and one patient was given a short course of oral corticosteroids. The mean (SD) length of time taking azithromycin, excluding those who stopped because of side effects, was 20 (10.1) months (range 4–38). Twenty six patients are continuing with the prophylaxis at the present time; in the other seven treatment was discontinued because of improvement in their condition. The mean (SD) length of time taking azithromycin, excluding those who stopped because of side effects, was 20 (10.1) months (range 4–38). Twenty six patients are continuing with the prophylaxis at the present time; in the other seven treatment was discontinued because of improvement in their condition. The mean (SD) length of time taking azithromycin, excluding those who stopped because of side effects, was 20 (10.1) months (range 4–38). Twenty six patients are continuing with the prophylaxis at the present time; in the other seven treatment was discontinued because of improvement in their condition. The mean (SD) length of time taking azithromycin, excluding those who stopped because of side effects, was 20 (10.1) months (range 4–38). Twenty six patients are continuing with the prophylaxis at the present time; in the other seven treatment was discontinued because of improvement in their condition.
Early life antibiotics and asthma

Cullinan et al present interesting data on the association between exposure to antibiotics in early life and the subsequent expression of atopy and asthma. In keeping with other studies, they report a positive association between antibiotic receipt over the first 5 years of life and asthma. The association was, however, largely accounted for by prescriptions issued for respiratory illnesses, and the authors conclude that reverse causation was the likely explanation for this association.

The inappropriate use of antibiotics for respiratory symptoms caused by unrecognised asthma is the main potential confounding factor in observational studies attempting to demonstrate a causal link between antibiotic receipt and atopic illnesses. It is certainly plausible that GPs may prescribe antibiotics in children with symptoms such as cough and wheeze in early life. Suggestions of a causal link are strengthened by demonstration of an association when antibiotics were used for symptoms not associated with asthma. The earlier study by Farooqi and Hopkins did, indeed, observe an association with non-respiratory use of antibiotics and asthma; in the study by Cullinan et al the association between non-respiratory indicated antibiotics and atopic asthma narrowly failed to reach statistical significance. The authors acknowledge that the study was only powered to show a doubling of the odds ratio for the association between early life antibiotic use and asthma, so an association remains possible in this cohort.

The most important limitation of the study, however, is the timing of the observed early life events in relation to secular changes in asthma prevalence and antibiotic prescribing, and hence the applicability of the results to modern day settings. This study observed events occurring 30 or more years ago in the parents of the Ashford birth cohort. As is well described, the prevalence of asthma has increased greatly over the last 30 years. There may also have been significant increases in antibiotic prescribing over this time. The subjects in this study received an average of 3.1 and a median of 5 antibiotic prescriptions over 5 years, while in a recent case-control study of 37 children with atopy and wheezing and 37 without either that the average and median number of antibiotic courses received during the first 5 years of life was 9.9 and 7 for wheezers and 6.3 and 5 for non-wheezers. There is also evidence of earlier prescribing of antibiotics in recent times; in our study group 89% of wheezers and 68% of non-wheezers received one or more courses of antibiotics in the first year, while in the Ashford study only 396 prescriptions were issued to 746 subjects in the first year, so a maximum of 53% children received any antibiotics.

It seems likely from the data presented that antibiotic exposure did not play a major causal role in promoting the asthma phenotype 30 years ago when both the prevalence of asthma and antibiotic prescribing to young children were significantly less than they are now, but the question of whether it may now be a significant and potentially modifiable factor remains unanswered.

M Thomas
Cotswold Cottage, Oakridge, Stroud GL6 7NZ, UK; mikelthomas@doctors.org.uk

References

www.thoraxjnl.com

Table 1 Change in symptoms while taking azithromycin prophylaxis

<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
<th>SD</th>
<th>SE</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sputum volume</td>
<td>1.6</td>
<td>0.8</td>
<td>0.16</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sputum colour</td>
<td>2.1</td>
<td>0.7</td>
<td>0.13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sputum consistency</td>
<td>2.5</td>
<td>0.6</td>
<td>0.11</td>
<td>0.006</td>
</tr>
<tr>
<td>Cough</td>
<td>2.4</td>
<td>0.7</td>
<td>0.12</td>
<td>0.001</td>
</tr>
<tr>
<td>Fatigue</td>
<td>2.1</td>
<td>1.0</td>
<td>0.18</td>
<td>0.002</td>
</tr>
<tr>
<td>Exercise tolerance</td>
<td>3.8</td>
<td>0.9</td>
<td>0.16</td>
<td>0.002</td>
</tr>
<tr>
<td>Wheeze</td>
<td>2.6</td>
<td>0.8</td>
<td>0.14</td>
<td>0.011</td>
</tr>
<tr>
<td>Breathlessness</td>
<td>2.3</td>
<td>0.7</td>
<td>0.13</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Symptoms scored on a 5-point scale: 1 = large decrease, 2 = decrease, 3 = no change, 4 = increase, 5 = large increase in symptoms.

S. aureus (n = 1), S. pneumoniae (n = 1). not done (n = 10). In three patients who had cultured P. aeruginosa before starting azithromycin prophylaxis the organism was not recultured at follow up.

In the 33 patients completing at least 4 months treatment there was a statistically significant reduction in infective exacerbations requiring oral antibiotics from a mean of 0.71 per month to 0.13 per month (p<0.001). There was also a reduction in the requirement for intravenous antibiotics from a mean of 0.08 courses per month to 0.03 courses per month (p<0.001).

Subgroup analysis of patients with P. aeruginosa isolated before starting azithromycin prophylaxis showed no difference compared with all patients included (p = 0.22). Twenty five patients had lung function tests before and after at least 4 months of treatment (range 4–20 months). There was an improvement in all lung function parameters but the improvement in carbon monoxide transfer factor (Tlco) was the only one to reach statistical significance (p = 0.01).

Symptom data were collected from 32 patients and scored on a 5-point scale (table 1). Statistical analysis using a non-parametric Wilcoxon test showed that there was a significant improvement in all symptoms.

The mechanism by which azithromycin reduces the number of infective exacerbations and chronic symptoms is unknown, but it is likely to be multifactorial. It may be due to downregulation of the host immune response by azithromycin, so decreasing host mediated tissue damage as postulated in the vicious circle hypothesis. It might also benefit patients by reducing bacterial load and therefore the stimulation for neutrophilic inflammation, or by influencing the pathogenic mechanisms of bacteria. Macrolide antibiotics have also been shown to reduce mucus secretion.

Currie et al compared high dosage amoxi- cillin with placebo over an 8 month period and found a greater reduction in the volume of purulent sputum between exacerbations in the amoxicillin group (20% of pretreatment volume) than in the placebo group, but did not demonstrate any reduction in infective exacerbations. The superior findings of this study suggest that the anti-inflammatory effects of azithromycin were important in achieving the results obtained. This study was performed with patients who were sufficiently well to preclude consideration of a placebo group. The patients therefore acted as their own controls. The results are sufficiently impressive to encourage the design of a randomised study, either enrolling less sick patients and having a placebo comparator or using a comparator antibiotic without immunomodulating properties.

G Davies, R Wilson
Host Defence Unit, Royal Brompton Hospital, London, UK
Correspondence to: Dr R Wilson, Host Defence Unit, Royal Brompton Hospital, Sidney Street, London SW3 6NP, UK; r.wilson@rbh.nthames.nhs.uk

References

www.thoraxjnl.com 541
Transfer factor (TLCO). All patients had diffuse bilateral ground glass opacities on a high resolution CT scan, most often sparing the subpleural areas (fig 1). Every patient improved following treatment with oral prednisone (0.5–0.9 mg/kg) but residual dyspnoea and reduced TLCO (<80% of predicted value) could be seen for more than 2 weeks.

Acute respiratory failure was attributed to inhalation of the waterproofing spray in view of the sudden occurrence of symptoms following exposure, the diffuse ground glass opacities without other abnormalities on the CT scans, and the absence of any other detected cause. In particular, BAL fluid was sterile for bacteria, mycobacteria, viruses and fungi. Serological tests for chlamydia and mycoplasma were performed on two patients and were negative. A nasal swab for influenza was performed on one patient and was negative.

We were, however, surprised that the patients used three different spray brands. Waterproofing sprays contain three types of components—a propellant gas (propane butane), a waterproofing agent (fluorocarbon resin), and a solvent. It appeared that the manufacturer of the fluorinated resin changed during the summer of 2002 (the same for the three brands) and that the isopropanol solvent had to be replaced with a heptane solvent. Consumers started complaining of respiratory symptoms in October 2002 and were negative. A nasal swab for influenza was performed on one patient and was negative.

In the past, several outbreaks of acute respiratory symptoms have been recorded in different countries including 550 in Oregon in 1992,5,6 in Pennsylvania and Virginia in 1993,7 in Quebec in 1993,8 and in Japan between 1992 and 1993.9 Most of these epidemics followed a modification of the composition of the spray. One untreated patient developed a pulmonary fibrosis during a German outbreak in the 1980s and one death was reported in Japan in the 1990s.10

Following these outbreaks various suggestions were proposed to explain these intoxications.11 In our opinion, the most likely explanation for the present outbreak is that the heptane solvent, which is more volatile than the previous one (isopropanol), allows the mist containing the new fluorinated resin to spread further in the tracheobronchial tree and to reach the alveoli where it might produce reactive metabolites inducing an alveolitis. However, the exact chemical reaction remains unknown. Because of the potentially lethal aspect of these intoxications and the possibility of new outbreaks, we consider that more research is needed on the effect of mist particle size and large analytical epidemiological studies are required to investigate this phenomenon further.

R Heinzer, J W Fitting
Service de pneumologie, CHUV, Lausanne, Switzerland
V Ribordy
Centre interdisciplinaire des urgences, CHUV, Lausanne, Switzerland
B Kuzoe
Hôpital du Samaritain, Vevey, Switzerland
R Lazor
Service de pneumologie, HUG, Genève, Switzerland

Correspondence to: Dr R Heinzer, c/o Beth Israel Deaconess Hospital, 330 Brookline Avenue, Stoneham 8, Boston, MA 02215, USA; rheinzer@rics.bwh.harvard.edu

References

Effect of PM10 on H influenzae and S pneumoniae

That air pollution, and specifically particles, are harmful to health is well accepted,1 causing direct effects such as lung inflammation resulting in exacerbations of lung and cardiac conditions2 and being associated with asthma.3 Air pollution in the 1960s Lawther et al showed that ambient particles stimulated the growth of Haemophilus influenzae in vitro,4 suggesting a direct effect of particles on bacteria themselves. However, it is not known whether this remains so for modern ambient particles where the sources are different.

To address this we have assessed the effect of PM10 (particles essentially less than 10 μm in diameter) on the respiratory pathogens commonly associated with acute exacerbations of chronic obstructive pulmonary disease (COPD) and pneumonia. The effect of dilutions of extracts of PM10 on the growth of H influenzae and Strepococcus pneumoniae grown in liquid broth and the effect of PM10 on microbial growth kinetics of S pneumoniae was assessed.

Fresh isolates of H influenzae and S pneumoniae obtained from clinical specimens and the control strains H influenzae NCTC 11931 and S pneumoniae ATCC 49619 were used. Particles were collected on a tapered element oscillating microbalance situated in central Birmingham, representative of an urban background site. To obtain a usable sample the surface of the filter was wetted and rinsed with two sequential aliquots of 0.5 ml saline using a Gilson pipette until visual inspection showed no more particles coming off the filter. The two aliquots were combined and sonicated for 2 minutes to disperse the particles and aggregates. This procedure usually gives a yield of 50–300 μg/ml particles (Donaldson, personal communication). It is not known for certain how these concentrations relate to likely concentrations in the epithelial lining fluid, but this approach has been used in previous in vitro studies of inflammatory responses which have shown pro-inflammatory effects.

In the first experiment a 1:20 dilution of PM10 was made by adding 0.5 ml to 9.5 ml iso-sensitest broth (ISTA; Oxoid Ltd, Basildon, UK) supplemented with 0.5% lyed horse blood and 20 μg/ml NAD. The same volume of normal saline was added to controls. Test and control bottles were inoculated with 0.5 ml of organism suspension at a density of 0.5 McFarland. A viable count was performed hourly for 5 hours while incubating at 37°C in 5% CO2 using the Miles and Misra technique.5 In the growth kinetic experiment equal volumes of PM10 solution and ISTA broth (supplemented with 5% lyed horse blood and 20 μg/ml NAD) were added to the first column of a sterile microtitre tray. Serial broth dilutions to a final dilution of 10−6 were performed. Cultured wells contained only broth and wells for sterility checks contained PM10 alone, broth alone and inoculum alone. Organism suspension, 50 μl S pneumoniae ATCC 49619, was added into each test and control column of the wells and incubated at 37°C in 5% CO2 for 5 hours. The Miles and Misra technique6 was used to estimate the viable count of organism in each well and the differences in log cfu/ml between test and control were plotted against serial dilutions of PM10. This test was repeated five times using the same strain to check for reproducibility.
In the first experiment the number of viable cells increased progressively and in the expected pattern over time (fig 1A and B), whether in the presence or absence of PM<sub>10</sub> for both H influenzae and S pneumoniae. In the growth kinetics experiment the only consistent finding was an inhibition of growth at a PM<sub>10</sub>:broth medium dilution of 1:1, possibly due to the diluted particles which are known to be able to exert pro-inflammatory effects in vitro. There was a constant inhibitory effect at a PM<sub>10</sub> dilution of 1:1, possibly due to the particles themselves or to dilution of the broth by the added saline. These findings suggest that the association of air pollution with hospital admissions for exacerbations of COPD and for pneumonia is probably not mediated through direct promotion of bacterial growth. If particles alone are responsible for these effects, they are likely to be mediated by particles causing lung inflammation, thus encouraging penetration and growth of bacteria in the respiratory tract. Alternatively, gaseous pollutants may be responsible for the epidemiological findings, either directly or in conjunction with particles. This interactive mechanism is supported by the association of ambient nitrogen dioxide levels with admissions for croup, and is analogous to the potential of the airway response to inhaled allergen by both nitrogen dioxide and ozone. Finally, it is possible that the particles have an effect on bacterial virulence and toxin production rather than growth. This possibility has not been tested here but warrants further study.

A Adedeji, T M A Weller
Department of Medical Microbiology, City Hospital, Birmingham B18 7QH, UK

J G Ayres
Department of Environmental and Occupational Medicine, University of Aberdeen AB25 2ZP, UK; j.g.ayres@abdn.ac.uk

References

Corrections
doi: 10.1136/thx.2003.008912corr1

In the paper entitled “Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma” by A Baldi, D Santini, F Vasaturo, et al published in the May 2004 issue of Thorax (2004;59:428-32) there was an error in the sentence beginning on line 14 of the left hand column on page 430. The sentence should have read “The median survival in patients with low p21 or p27 expression was shorter than in those with high p21 or p27 expression.” The publishers apologise for this error.